Ancora Biotech is a clinical-stage biopharmaceutical company developing breakthrough biotherapeutics for B cell cancers, metabolic diseases, and chronic hepatitis B infection. Formed by former Teneobio executives and venture investors, it oversees three therapeutic programs across separate spinoffs — TeneoTwo (TNB-486, a T cell engager in Phase I… - View it on GitHub